標題: High Effectiveness in Actions of Carfilzomib on Delayed-Rectifier K+ Current and on Spontaneous Action Potentials
作者: So, Edmund Cheung
Liu, Ping-Yen
Lee, Chien-Ching
Wu, Sheng-Nan
影像與生醫光電研究所
Institute of Imaging and Biomedical Photonics
關鍵字: carfilzomib;delayed-rectifier K+ current;current inactivation;M-type K+ current;action potential;pituitary cell;vascular smooth muscle cell;heart cell
公開日期: 7-十月-2019
摘要: Carfilzomib (CFZ, Kyprolis (R)) is widely recognized as an irreversible inhibitor of proteasome activity; however, its actions on ion currents in electrically excitable cells are largely unresolved. The possible actions of CFZ on ionic currents and membrane potential in pituitary GH(3), A7r5 vascular smooth muscle, and heart-derived H9c2 cells were extensively investigated in this study. The presence of CFZ suppressed the amplitude of delayed-rectifier K+ current (I-K(DR)) in a time-, state-, and concentration-dependent manner in pituitary GH(3) cells. Based on minimal reaction scheme, the value of dissociation constant for CFZ-induced open-channel block of I-K(DR) in these cells was 0.33 mu M, which is similar to the IC50 value (0.32 mu M) used for its efficacy on inhibition of I-K(DR) amplitude. Recovery from I-K(DR) block by CFZ (0.3 mu M and 1 mu M) could be well fitted by single exponential with 447 and 645 ms, respectively. The M-type K+ current, another type of K+ current elicited by low-threshold potential, was slightly suppressed by CFZ (1 mu M). Under current-clamp condition, addition of CFZ depolarized GH(3) cells, broadened the duration of action potentials as well as raised the firing frequency. In A7r5 vascular smooth muscle cells or H9c2 cardiac cells, the CFZ-induced inhibition of I-K(DR) remained efficacious. Therefore, our study led us to reflect that CFZ or other structurally similar compounds should somehow act on the activity of membrane K-V channels through which they influence the functional activities in different types of electrically excitable cells such as endocrine, neuroendocrine cells, smooth muscle cells, or heart cells, if similar in vivo findings occur.
URI: http://dx.doi.org/10.3389/fphar.2019.01163
http://hdl.handle.net/11536/153158
ISSN: 1663-9812
DOI: 10.3389/fphar.2019.01163
期刊: FRONTIERS IN PHARMACOLOGY
Volume: 10
起始頁: 0
結束頁: 0
顯示於類別:期刊論文